In this episode, we discuss two agents newly approved for schizophrenia -- Rexulti (brexpiprazole) and cariprazine (Vraylar).

In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.

In this podcast, we discuss three new injectable insulin formations: Toujeo (insulin glargine U-300), Humalog U-200 (insulin lispro), and Tresiba (insulin degludec).

In this episode, we discuss PCSK9 inhibitors, a new drug class for LDL lowering, with a particular focus on alirocumab (Praluent).

In this episode, we discuss the new drug class, ARNI, recently approved for heart failure with a focus on sacubatril/valsartan (Entresto) and the PARADIGM-HF trial.

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for tacrolimus (Prograf) and lithium.

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for valproic acid (Depakote/Depakene/Depakon) and digoxin (Lanoxin).

In this episode, we discuss the therapeutic drug monitoring and dose adjustments for warfarin (Coumadin) and phenytoin (Dilantin).

In this episode, we discuss malaria prophylaxis with atovaquone/proguanil, chloroquine, hydroxychloroquine, doxycycline, mefloquine, and primaquine.

In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 2 of a 2 part episode.

In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years.  This is part 1 of a 2 part episode.

In this episode, we interview Brad Cannon, PharmD regarding his career path in pharmacy and his viewpoints on the pharmacy profession.

In this episode, we discuss the optimal drug therapy for three different case vignettes -- depression, hypertension, and diabetes mellitus.

In this episode, we review historical and new treatment options for hepatitis C, including: peginterferon, rivabirin, boceprevir, telaprevir, sofosbuvir (Sovaldi), simeprevir (Olysio), ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak), and ledipasvir/sofosbuvir (Harvoni).

May 18, 2015 - Correction added in the beginning of the episode regarding Viekira Pak dosing regimen.

In this episode, we discuss the pharmacology of oversedation, the importance of sedation minimization strategies in mechanically ventilated patients, and overview the sedatives and analgesics commonly used in this patient population.

In this episode, we discuss risk factors for opioid-related adverse events, naloxone (Narcan, Evzio), and a number of non-narcotic agents for neuropathic pain.

In this episode, we summarize and discuss the clinical implications of the SMART trial (Salmeterol Multicenter Asthma Research Trial; Nelson et al, 2006).